Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001486 · ClinicalTrials.gov registry record
Genetic Study of Schizophrenia
A clinical trial of Schizophrenia and Schizoaffective Disorder, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- 4,914
- Enrollment target
- 1
- Study location
NCT00001486: Completed study of Schizophrenia and Schizoaffective Disorder, sponsored by National Institute of Mental Health (NIMH).
NCT00001486 is a study of Schizophrenia and Schizoaffective Disorder that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 4,914 participants, above the 203-participant average among 315 other Schizophrenia trials with a reported enrollment target (2321% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001486, a study of Schizophrenia and Schizoaffective Disorder, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- 4,914 participants
- Enrollment target
- 1
- Study location
Study Summary
This large ongoing study at NIMH investigates the neurobiology of schizophrenia by identifying susceptibility genes, evaluating their impact on brain function to better understand how to treat and prevent this illness.
Primary Outcome
genotyping analysis
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,914 participants |
| Start Date | 1995-07-15 |
What the finished NCT00001486 record still lists
NCT00001486 is an observational study that tracks outcomes without assigning an intervention. Its 4,914 participants enrollment target places it among the larger protocols in the corpus, above the 203-participant average among 315 other Schizophrenia trials with a reported enrollment target (2321% higher).
The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 0 interventions.
NCT00001486 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00001486 about?
NCT00001486 is a clinical study titled "Genetic Study of Schizophrenia". This large ongoing study at NIMH investigates the neurobiology of schizophrenia by identifying susceptibility genes, evaluating their impact on brain function to better understand how to treat and prevent this illness.
What is the current status of trial NCT00001486?
This trial is currently completed. The enrollment target is 4,914 participants. The study started on 1995-07-15.
What conditions does trial NCT00001486 study?
This clinical trial studies the following conditions: Schizophrenia, Schizoaffective Disorder.
Who is sponsoring clinical trial NCT00001486?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001486 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00001486's enrollment target sits among peer trials
4,914 1st of 315 higher than 315 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
RECRUITING · NA
-
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
RECRUITING · Phase 4
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05929976 · 4,900 participants
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
- NCT05252754 · 4,874 participants · Phase 3
Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI